Loading...
XTAI
4133
Market cap39mUSD
Aug 28, Last price  
20.60TWD
Name

Abnova Taiwan Corp

Chart & performance

D1W1MN
XTAI:4133 chart
P/E
P/S
3.55
EPS
Div yield, %
4.37%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
-5.10%
Revenues
Net income
CFO
Dividend
Jun 16, 20260.112 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Abnova (Taiwan) Corporation specializes in the development and distribution of a comprehensive range of recombinant proteins and antibodies. The company's extensive product portfolio caters to diverse research and diagnostic applications, featuring specialized reagents for SARS-CoV/CoV-2, nucleic acids (both DNA and RNA), and various proteins and peptides. Their offerings further include items like DNAxPab, laboratory beads, dyes, cellular lysates, microscopic slides, antibody pairs and associated kits, as well as antibody and tissue arrays. Additionally, they provide in situ hybridization products, advanced laboratory systems and automation, GMP-grade and analyte-specific reagents, and solutions for in vitro diagnostics. Beyond these product lines, Abnova supplies a broad spectrum of antibody types, such as MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and those specifically targeting circulating rare cells. The company also delivers integrated solutions and services, encompassing gene synthesis and cytogenetic analysis, peptide services, protein expression and conjugations, custom antibody generation, and assay development. Abnova (Taiwan) Corporation operates from its headquarters in Taipei, Taiwan.
IPO date
May 27, 2008
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

No data to show